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Background: Efﬁcient localized cervicovaginal antibacterial therapy, enabling the delivery
of antibiotic to the site of action at lower doses while escaping systemic drug effects and
reducing the risk of developing microbial resistance, is attracting considerable attention.
Liposomes have been shown to allow sustained drug release into vaginal mucosa and
improve delivery of antibiotics to bacterial cells and bioﬁlms. Azithromycin (AZI), a potent
broad-spectrum macrolide antibiotic, has not yet been investigated for localized therapy of
cervicovaginal infections, although it is administered orally for the treatment of sexually
transmitted diseases. Encapsulation of AZI in liposomes could improve its solubility, anti-
bacterial activity, and allow the prolonged drug release in the cervicovaginal tissue, while
avoiding systemic side effects.
Purpose: The objective of this study was to develop AZI-liposomes and explore their
potentials for treating cervicovaginal infections.
Methods: AZI-liposomes that differed in bilayer elasticity/rigidity and surface charge were
prepared and evaluated under simulated cervicovaginal conditions to yield optimized lipo-
somes, which were assessed for antibacterial activity against several planktonic and bioﬁlm-
forming Escherichia coli strains and intracellular Chlamydia trachomatis, ex vivo AZI
vaginal deposition/penetration, and in vitro cytotoxicity toward cervical cells.
Results: Negatively charged liposomes with rigid bilayers (CL-3), propylene glycol lipo-
somes (PGL-2) and deformable propylene glycol liposomes (DPGL-2) were efﬁcient against
planktonic E. coli ATCC 700928 and K-12. CL-3 was superior for preventing the formation
of E. coli ATCC 700928 and K-12 bioﬁlms, with IC50 values (concentrations that inhibit
bioﬁlm viability by 50%) up to 8-fold lower than those of the control (free AZI). DPGL-2
was the most promising for eradication of already formed E. coli bioﬁlms and for treating C.
trachomatis infections. All AZI-liposomes were biocompatible with cervical cells and
improved localization of the drug inside vaginal tissue compared with the control.
Conclusion: The performed studies conﬁrm the potentials of AZI-liposomes for localized
cervicovaginal therapy.
Keywords: vaginal drug delivery, bioﬁlm, Escherichia coli, Chlamydia trachomatis,
cervical cells, biocompatibility
Introduction
Bacterial cervicovaginal diseases, such as sexually transmitted Chlamydia tracho-
matis infections, recurrent bacterial vaginosis, and urogenital infections caused by
Escherichia coli, represent a major public health problem with a substantial and
expanding economic burden on the healthcare system. Vaginal E. coli strains are
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considered to be a reservoir for vaginal and/or endocervi-
cal colonization in pregnant women, which may result in
progression of urinary tract, intra-amniotic and postpartum
infections. Consequently, maternal or fetal complications
can occur, including postpartum endometritis, bacteremia
or sepsis.1 Untreated C. trachomatis infections may lead to
infertility, adverse pregnancy outcomes, fetal loss and an
increased risk of HIV transmission.2
The recommended treatment regimens for genital
E. coli and C. trachomatis infections include oral admin-
istration of antibiotics.3,4 However, the incidence of anti-
biotic-related side effects and concerns about bacterial
resistance make it necessary to consider other modes of
tackling cervicovaginal infections, such as those based on
localized cervicovaginal therapy.
Application of liposomally encapsulated antibiotics pre-
sents a promising strategy for enhanced drug delivery to
bacterial cells and bioﬁlms.5–7 Due to their phospholipid com-
position, liposomes are of particular interest regarding the
safety issue and targeting ability.8 Tuning the physicochemical
properties of liposomes, such as bilayer composition and
ﬂuidity, size, surface charge and coating, allows the develop-
ment of drug-containing liposomes for localized therapy.9,10
Azithromycin (AZI) is a potent, broad-spectrum
macrolide antibiotic that is available in dosage forms for
oral, ophthalmic and parenteral administration. It is recom-
mended for the treatment of respiratory, skin and soft
tissue infections, including sexually transmitted bacterial
diseases caused by C. trachomatis and Neisseria
gonorrhoeae.11,12 AZI is usually available as a dihydrate
(Mw 785) and is characterized by its limited solubility in
water (log P=3.98).13 Incorporation of AZI into liposomes
could increase its solubility, favor its cervicovaginal bio-
compatibility, and enable prolonged AZI release, permit-
ting higher local drug concentrations.
Although AZI-liposomes have been tested against sev-
eral pathogens,14–18 to the best of our knowledge, they
have not been investigated for localized treatment of vagi-
nal infections, and conventional topical formulations of
AZI are not available for vaginal administration.
Therefore, for the ﬁrst time, we investigated the potential
of several types of AZI-liposomes, ie, conventional (CLs),
propylene glycol (PGLs) and deformable propylene glycol
liposomes (DPGLs), for the treatment of cervicovaginal
infections. The different AZI-liposomes were characterized
for the physical properties, in vitro release under simulated
cervicovaginal conditions, and storage stability. The opti-
mized liposomes were examined for ex vivo permeability
on porcine vaginal mucosa, and their in vitro antibacterial
activity was tested against several strains of bioﬁlm-forming
E. coli and intracellular C. trachomatis. Finally, the biocom-
patibility of the different AZI-liposomes was estimated in an
in vitro cervical cell model.
To the best of our knowledge, AZI-liposomes have not
yet been assessed against C. trachomatis and bioﬁlm-
forming E. coli, and their in vitro compatibility with cer-
vical cells has not yet been examined. Moreover, this study
is the ﬁrst to employ direct quantitative polymerase chain
reaction (qPCR) measurements to study the antichlamydial
effect of liposomally encapsulated antibiotics. Finally, the
use of monoacyl phosphatidylcholine as an edge activator
for the preparation of DPGLs represents a novel approach
for the development of liposomes with elastic bilayers.
Materials and methods
Materials
Egg phosphatidylcholine (EPC), egg phosphatidylglycerol
sodium salt (EPG), hydrogenated soybean phosphatidyl-
choline (SPC-3) and monoacyl phosphatidylcholine from
soybean (SLPC-80) were kindly donated by Lipoid GmbH
(Ludwigshafen, Germany). AZI in the form of a dihydrate
was a gift from PLIVA Croatia Ltd. (Zagreb, Croatia).
Sephadex G-50, urea, glucose, lactic acid, Dulbecco’s
modiﬁed Eagle’s medium, Minimum Essential Medium
with Earle’s salts, L-glutamine, fetal bovine serum and
bovine serum albumin were obtained by Sigma-Aldrich
(St. Louis, USA). Acetonitrile, ethanol and methanol
were of HPLC grade and purchased from BDH Prolabo
(Lutterworth, UK). Luria-Bertani (LB) agar and LB broth
were obtained from Fisher Scientiﬁc (Leicestershire, UK)
and Serva Electrophoresis GmbH (Heidelberg, Germany),
respectively. Heat-inactivated fetal bovine serum was pur-
chased from Euroclone (Pero, Italy). All other solvents or
chemicals used in this research were of analytical grade
and obtained from Kemika (Zagreb, Croatia) or Sigma-
Aldrich.
A solution of 0.01 M phosphate-buffered saline
(PBS, pH 7.5) was prepared and ﬁltered according to
Rukavina et al17. Vaginal ﬂuid simulant (VFS) was
made by dissolving 0.222 g of Ca(OH)2, 1.40 g of
KOH, 3.51 g of NaCl, 2 g of lactic acid, 1 g of acetic
acid, 0.16 g of glycerol, 0.4 g of urea, 5 g of glucose
and 0.018 g of bovine serum albumin in demineralized
water (up to 1000 ml) and adjusting the pH to 4.5 by the
addition of 0.1 M HCl.19 Commercially available PBS,
Vanić et al Dovepress
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pH 7.3–7.5 (Lonza, Verviers, Belgium), was used in
antibacterial assays against E. coli.
Preparation of AZI-liposomes
CLs were prepared by a modiﬁed proliposome method.20
In brief, phospholipids and the drug (Table 1) were dis-
solved in warm ethanol (300 mg), followed by the addition
of 0.5 ml of PBS, pH 7.5, with continuous magnetic
stirring (600 rpm, 60°C) to yield an initial proliposome
mixture. This mixture was cooled to room temperature and
then transformed into a liposomal dispersion by slow
addition of PBS, pH 7.5, to a ﬁnal volume of 10 ml of
liposome dispersion. The dispersion was stirred (600 rpm)
for approximately 45 min at room temperature, while in
the case of liposomes embedding SPC-3 (denoted as CL-2
and CL-3), the whole procedure was performed at approxi-
mately 50°C.
For the preparation of elastic liposomes (PGLs and
DPGLs), the selected phospholipids and AZI (Table 1)
were dissolved in propylene glycol using a magnetic stirrer
(600 rpm, 50°C). Then, 1 ml of PBS, pH 7.5 (heated to the
same temperature) was added. The mixture was stirred for
approximately 2 min (50°C) and diluted to a liposomal
dispersion by dropwise addition of 8 ml of PBS, pH 7.5,
with continuous magnetic stirring (45 min).
The corresponding empty liposomes were prepared
under the same conditions, omitting AZI, and were used
as controls in in vitro antibacterial and biocompatibility
studies.
All the liposomal dispersions were hand-extruded
(LiposoFast Basic, Avestin, Canada) through 400 nm poly-
carbonate membranes (3 cycles) at room temperature and
stored at 4°C. The extrusion of CL-2 and CL-3 was per-
formed at 50°C.
Size and zeta potential measurements
The mean diameters, polydispersity indexes (PDIs) and
zeta potentials of all the prepared liposomes were deter-
mined on a Zetasizer 3000HS (Malvern Instruments,
Malvern, UK) at 25°C using a scattering angle of 90°
(size measurements) and a capillary cell with an optical
modulator at 1,000 Hz (zeta potential measurements).
Prior to the measurements, the instrument was calibrated
with Malvern’s size and zeta potential standards. The
liposomal samples were prepared by diluting the liposomal
dispersions with PBS, pH 7.5, to achieve appropriate count
rates.21 The measurements were also performed in VFS,
pH 4.5, at 37°C and 25°C.
Determination of liposome bilayer
elasticity/rigidity
The elasticities/rigidities of the different AZI-liposome
bilayers were determined using a previously reported
method.22 In brief, liposomes were extruded through a
100 nm pore-sized membrane (rp) for 5 min at an external
pressure of 2.5 bar. The mass of the extruded liposomes (J)
and the mean diameter of the liposomes after extrusion (rv)
were determined. The degree of bilayer elasticity (E) was
calculated by applying the following equation:21
E ¼ J  rv=rp
 2
Encapsulation efﬁciency determination
and quantiﬁcation of AZI
The encapsulation of AZI in the different liposomes was
determined after separation of unencapsulated AZI by a
minicoloumn centrifugation method.23 In brief, minicol-
umns ﬁlled with Sephadex G-50 gel were dried by
Table 1 Composition of liposomes
Liposomes type Code EPC (mg) EPG (mg) SPC-3 (mg) SLPC-80 (mg) AZI (mg) PG (g) PBS, pH 7.5 (ml)
CLs CL-1 190 10 - - 30 - 10
CL-2 150 - 50 - 30 - 10
CL-3 140 10 50 - 30 - 10
PGLs* PGL-1 200 - - - 30 1 9
PGL-2 190 10 - - 30 1 9
DPGLs* DPGL-1 170 - - 30 30 1 9
DPGL-2 160 10 - 30 30 1 9
Notes: The ﬁnal volume of liposome dispersion was 10 ml. *Elastic liposomes.
Abbreviations: AZI, azithromycin; CLs, conventional liposomes; DPGLs, deformable propylene glycol liposomes; EPC, egg phosphytidylcholine; EPG, egg phosphatidylgly-
cerol sodium salt; PBS, phosphate-buffered saline; PG, propylene glycol; PGLs, propylene glycol liposomes; SLPC-80, soybean monoacyl phosphatidylcholine; SPC-3,
hydrogenated soybean phosphatidylcholine.
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centrifugation (2,000 rpm, 3 min). Then, 0.4 ml of lipo-
some dispersions were cautiously applied to the top of the
gels, followed by centrifugation under the same conditions
to obtain AZI-liposomes in the centrifuge tubes, which
were saved for assessment. Subsequently, 0.5 ml of PBS,
pH 7.5, was added to each minicolumn, which was again
centrifuged, and the eluates were collected. The last pro-
cedure, including rinsing the minicolumns with PBS, was
repeated until all unencapsulated AZI was removed.
Quantiﬁcation of AZI, both unencapsulated and lipo-
somally encapsulated, was performed by HPLC under the
previously described conditions.17
The encapsulation of AZI was expressed as the encapsu-
lation efﬁciency (%), ie, the percentage of encapsulated AZI
compared to the original drug concentration and the amount
of encapsulated drug per mass of phospholipids used.
In vitro release studies
The release of AZI from the different liposomes, which were
previously separated from the unencapsulated drug, was
assessed under conditions simulating vaginal environment
using the so-called bag dialysis method. AZI-liposomes (cor-
responding to 1 mg of AZI) were placed in a dialysis bag (Mw
cut off 12–14,000 Da, Medicell Membranes Ltd., London,
UK) and dialyzed against 25ml of VFS (pH 4.5) with constant
stirring (50 rpm) and incubation at 37°C. Aliquots (2 ml),
containing the released drug, were collected at predetermined
time intervals (1, 2, 3, 4, 5, 6 and 24 h) and immediately
replaced with the same volume of fresh VFS, pH 4.5. The
amount of released drug was determined by HPLC.17
To investigate the inﬂuence of pH on AZI release and
to mimic cervical conditions, studies were also performed
in PBS, pH 7.5. Free AZI dissolved in a mixture of ethanol
and demineralized water (6/4, v/v) served as a control and
was examined at pH 7.5.
Storage stability studies
The changes in the physical properties of AZI-liposomes
(mean diameters, PDIs and zeta potentials) were monitored
during storage of the liposome dispersions for 8months at 4°C.
The measurements were performed at 25°C.
Ex vivo vaginal deposition/penetration
studies
Porcine vaginal mucosa was used to evaluate the deposition/
penetration of AZI from the selected AZI-liposomes. The
vaginal tissues from the adult animals (approximately 1 year
old) were received as waste from a local slaughterhouse. The
vaginal tissue was carefully separated from the underlying
tissue, cleaned with physiological solution (0.9% NaCl), cut
into smaller pieces (approximately 3×3 cm) and frozen at
−20°C. Approximately 30 min prior to the experiments, the
vaginal tissue was defrosted and pre-equilibrated in VFS for
15 min. The vaginal tissue (900–1,050 µm thick) was ﬁxed
between the donor and acceptor chamber of the Franz cell
(3.14 cm2, surface area), with the vaginal epithelium facing
the donor chamber. The acceptor chamber (15 ml) was ﬁlled
with PBS, pH 7.5, and constantly stirred (200 rpm). The
whole system was maintained at 37±1°C. Samples of AZI-
liposomes or the control (free AZI, 6/4, ethanol/water solu-
tion), equivalent to 1 mg of AZI, were added to the donor
chamber and covered with paraﬁlm. The acceptor medium
(500 µl) was sampled at intervals of 1, 2, 3, 4, 5, 6 and 24 h
and immediately replenished with the same volume of fresh
PBS. After 24 h, the liquid (if remained) in the donor cham-
ber was removed by pipetting, and the vaginal surface was
carefully washed with methanol. Both fractions were mixed
together and dissolved in methanol, indicating nonpenetrat-
ing AZI. The vaginal tissue was then shred and extracted
with methanol (4 h, agitation) to determine the drug that
remained inside the vaginal tissue. The AZI content in all
the collected samples was quantiﬁed by HPLC.17
Antibacterial assays against E. coli
Bacterial strains and growth conditions
The three E. coli strains (ATCC 8739, ATCC 700928 and
K-12) were stored in 20% glycerol stocks at −70°C.
Working stocks of each strain were prepared on LB agar
plates and stored at +4°C. For liquid cultures, a 1 µl
inoculation loop full of colonies was transferred to 3 ml
of LB broth and incubated under aerobic conditions (37°C,
220 rpm) overnight. The overnight cultures were diluted in
LB broth and incubated until they reached exponential
growth, corresponding to approximately 108 colony form-
ing units per milliliter (CFU/ml). The bacterial concentra-
tion was estimated by measuring the turbidity at 595 nm
using a Varioskan Flash Multimode plate reader (Thermo
Fisher Scientiﬁc, Vantaa, Finland) and further conﬁrmed
by serially diluting and plating the cultures on LB agar for
the determination of CFU/ml.
In vitro antibacterial activity against bioﬁlm and
planktonic E. coli
The anti-bioﬁlm activity of the selected AZI-liposomes
(CL-3, PGL-2 and DPGL-2) toward E. coli strains was
Vanić et al Dovepress
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tested and compared to the activity of free AZI (6/4, v/v,
ethanol/water solution) and the corresponding empty lipo-
somes (without encapsulated AZI).
Two-fold dilution series of AZI-liposomes and free
AZI (solution) were prepared in LB and tested at eight
concentrations ranging from 0.61 µg/ml to 78.50 µg/ml.
The studies were performed in two modes, pre- and post-
bioﬁlm formation.24 In both cases, exponentially grown
bacterial cultures, diluted to a concentration of 106 CFU/
ml, were used. Brieﬂy, in the pre-exposure mode of the
assay, bacteria and AZI samples were simultaneously
added to NuncTM 96-well polystyrene microplates
(NunclonTM Delta surface) at a ﬁnal volume of 200 µl.
The plates were incubated at 37°C, 200 rpm, for 18 h. For
the postexposure mode, bacteria were initially added to the
microtiter well plates (200 µl) and allowed to form bio-
ﬁlms for 18 h (37°C, 200 rpm). After 18 h, the planktonic
bacterial phase was discarded, and the AZI samples (pre-
pared as described above) and fresh culture medium were
added to the wells. The plates were further incubated for
24 h (37°C, 200 rpm). The samples were tested in dupli-
cate in four independent experiments. Empty liposomes
(without AZI) were always included as a negative control,
and a mixture of ethanol and water was included as a
solvent control, in addition to the wells that contained
only medium and untreated bacteria.
Anti-bioﬁlm activity was quantiﬁed using a resazurin
(redox) staining assay.24 At the end of the incubation
periods with the compounds (in the pre-exposure and
postexposure modes), the planktonic phase was removed,
and the bioﬁlms were washed once with PBS. Resazurin
solution in PBS (20 µM) was added to the wells (200 µl),
and the plates were incubated at room temperature for 1 h.
Fluorescence was measured (λex =560 nm, λem =590 nm)
using a Varioskan Flash Multimode plate reader using a
top ﬂuorescence reading. Anti-bioﬁlm activity was deter-
mined as the inhibition percentage compared to untreated
bioﬁlms. The concentrations of the samples that inhibited
bioﬁlm viability by 50% (IC50) were calculated from eight
concentration points via nonlinear regression analysis
using GraphPad Prism 6.0 software.
Additionally, antibacterial activity against planktonic
bacteria was assessed spectrophotometrically. At the end
of the 18 hr incubation period (in the pre-exposure mode
of the assay), bacterial turbidity was recorded at 620 nm
using a Varioskan Flash Multimode plate reader.
Antibacterial effects were determined as inhibition percen-
tages compared to untreated bacteria. The concentrations
of the samples that inhibited bacterial growth by 50%
(minimum inhibitory concentrations, MIC50) were deter-
mined as described above.
In vitro antibacterial assay against
intracellular C. trachomatis
Bacterial strain
The C. trachomatis serovar D (UW-3/CX, ATCC) strain
was propagated and partially puriﬁed according to pre-
viously described methods.25,26 Brieﬂy, DEAE-dextran
(45 mg/ml in Hanks’ balanced salt solution) treated
McCoy cells were infected with C. trachomatis serovar
D, and incubated for 48 h in Minimal Essential Medium
with Earle salts supplemented with 10% fetal bovine
serum, 8 mmol/l HEPES, 0.5% glucose, 1× nonessential
amino acids, 2 mmol/l L-glutamine, 25 µg/ml gentamicin
and 1 µg/ml cycloheximide. Infected cells were lysed by 2
freeze-thaw cycles in sucrose-phosphate-glutamic acid
buffer 48 h post-infection. The cell lysate was centrifuged
(800 g, 10 min) and the supernatant containing the chla-
mydial elementary bodies were used for subsequent
experiments. The titer of the chlamydial stock was calcu-
lated by infecting McCoy cells and counting the inclusion
numbers 48 h post-infection with a monoclonal anti-chla-
mydia LPS antibody (AbD Serotec, Oxford, United
Kingdom) and a FITC-labeled anti-mouse IgG (Sigma-
Aldrich, St. Louis, MO).
Culture and infection of HeLa cells with C. trachomatis in
the presence of AZI-liposomes and free AZI
HeLa 229 cells (ATCC) (40,000 cells/well) were cultured
in 96-well microtiter plates (Sarstedt, Nümbrecht,
Germany) in 100 μl of Minimum Essential Medium sup-
plemented with Earle’s salts, 10% heat-inactivated fetal
bovine serum, 1× nonessential amino acids, 8 mmol/l
HEPES, 2 mmol/l L-glutamine, 1 µg/ml fungisone and
25 μg/ml gentamycin. The cells were incubated overnight
at 37°C in 5% CO2 to obtain a 90% conﬂuent cell layer.
27
HeLa cells were washed twice with 100 μl of PBS, pH 7,
per well and infected with C. trachomatis (multiplicity of
infection, MOI 0.2) as described previously.28 After infec-
tion, the HeLa cells were washed twice with PBS and
cultured in cycloheximide-free medium supplemented
with a dilution series of the applied AZI samples (n=3).
A concentration range of 0.5–0.0002 μg/ml AZI for AZI-
liposomes (CL-3, PGL-2 and DPGL-2) and free AZI
(solution) was tested. The cells were incubated for 48 h
at 37°C in 5% CO2.
Dovepress Vanić et al
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Cell lysis and direct quantitative polymerase chain
reaction (qPCR) measurements
Direct qPCR was performed according to Eszik et al28.
Brieﬂy, 48 h post infection, the HeLa cells were washed
twice with 100 µl/well PBS. Finally, 100 μl of Milli-Q water
(Millipore, Billerica, MA, USA) was added to the wells,
and two freeze-thaw cycles were performed. The mixed cell
lysates were used as templates in qPCR for chlamydial
genomic DNA quantitation. qPCR was performed using
the C. trachomatis pykF gene-speciﬁc primers in a Bio-
Rad CFX96 real-time system (Bio-Rad, Hercules, CA,
USA). The primer sequences were: pykF forward: 5′-
GTTGCCAACGCCATTTACGATGGA-3′, pykF reverse:
5′-TGCATGTACAGGATGGGCTCCTAA-3ʹ. Two micro-
liters of 5x HOT FIREPol® EvaGreen® qPCR Supermix
(Solis BioDyne, Tartu, Estonia), 10 pmol of qPCR primers,
1 μl of cell lysate template and 5 µl of Milli-Q water were
used per reaction. The qPCR cycle parameters were as
follows: 12 min at 95°C for polymerase activation, 40
cycles at 95°C for 20 s and 64°C for 1 min, and a melting
curve analysis step for speciﬁcity testing. Cycle threshold
(Ct) levels were calculated for each sample. Minimum
inhibitory concentration (MIC) values for C. trachomatis
were identiﬁed as previously described.28
In vitro biocompatibility studies
Cell culturing
HeLa cells were cultured as monolayers and maintained in
Dulbecco’s modiﬁed Eagle’s medium supplemented with
10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml
penicillin and 100 μg/ml streptomycin in a humidiﬁed
atmosphere with 5% CO2 at 37°C.
Cell toxicity study
The cells were inoculated onto 96-well microtiter plates at
concentrations of 1.6×104 cells/ml. AZI-liposomes (CL-3,
PGL-2 and DPGL-2) or free AZI (6/4, v/v, ethanol/water
solution) was added the next day at ﬁve dilutions
(39.25 µg/ml, 19.63 µg/ml, 9.81 µg/ml and 2.45 µg/ml
and 1.23 µg/ml) and incubated with the cells for an addi-
tional 24 h (37°C, 5% CO2). The cell viability was eval-
uated by the MTT assay, a colorimetric assay system that
measures the reduction of a tetrazolium component (MTT)
into an insoluble formazan product by the mitochondria of
viable cells.29 The absorbance was determined spectro-
photometrically at 570 nm on a microplate reader
(Multiscan, Thermo Labsystems, Waltham, MA, USA)
and was directly proportional to the cell viability. The
cell viability of the treated cells was expressed as a per-
centage compared to the untreated control cells. Each
result represents an average value from at least three
separate experiments performed in quadruplicate.
Statistical analysis
Statistical data analyses were performed using the
GraphPad 5.0 Prism program (GraphPad Software, Inc.,
San Diego, USA). Student’s t-test was applied for compar-
isons between two groups, and means were considered
signiﬁcantly different when p<0.05. One-way ANOVA
and Tukey’s multiple comparison test, with p<0.05 set as
the minimal level of signiﬁcance, were applied for com-
parisons of three or more groups.
Results and discussion
Characterization of liposomes
A suitable characterization of liposomes is crucial for
obtaining reliable data with high translational output.30
Namely, the physicochemical properties of liposomes
inﬂuence their stability in biological environments and
during storage, determine the pharmacokinetic properties
of the encapsulated drug and contribute toward their beha-
vior within the biological milieu, subsequently affecting
the efﬁciency of therapy. Therefore, the ﬁrst phase in the
present study focused on assessing the physical character-
istics of AZI-liposomes that differed in terms of bilayer
composition, the presence of cosolvent and the edge acti-
vator (Table 1). Liposomes were evaluated for size and
surface charge (Tables 2 and 3), bilayer elasticity (Table 4)
and encapsulation efﬁciency (Figure 1).
As presented in Table 2, AZI-liposomes composed of
only neutral phospholipids (CL-2, PGL-1 and DPGL-1)
were signiﬁcantly larger (544–840 nm), with broad size
distributions (PDI>0.49), than the corresponding lipo-
somes containing negatively charged EPG (CL-3, PGL-2
and DPGL-2) (t-test, p<0.05). Extrusion of all AZI-lipo-
somes signiﬁcantly decreased their mean diameters (189–
261 nm) and PDIs (0.17–0.27) (t-test, p<0.05). The only
exception was PGL-1 with PDI >0.7, indicating a tendency
of PGL-1 to form aggregates in the presence of propylene
glycol and the absence of a negatively charged phospholi-
pid, which both affect the size of the liposomes.
Comparison of the various types of negatively charged
liposomes (CL-1, CL-3, PGL-2 and DPGL-2) revealed
DPGL-2 as the smallest. These results are in agreement
with previously published ﬁndings showing the ability of
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an edge activator to reduce the size of deformable
liposomes,21,23 which might be attributed to the enhanced
elasticity (ﬂexibility) and decreased surface tension of the
liposomes in the presence of single chain surfactants.31
Moreover, a decrease in the size of microemulsions con-
taining an increased ratio of monoacyl phosphatidylcho-
line (used as the edge activator in DPGLs in the present
study) has been conﬁrmed by Hoppel et al32.
The zeta potential values (Table 2) followed the proper-
ties of the materials used for the preparation of liposomes.
Liposomes prepared without EPG had zeta potentials
between −17 and −21 mV, while those containing EPG
had strongly negative zeta potentials higher than −50 mV,
indicating the formation of physically stable liposome
dispersions.
To resemble more closely the conditions AZI-liposomes
will be exposed to, the evaluation of their physicochemical
properties was also performed at simulated vaginal conditions
(VFS, pH 4.5, 37°C). Moreover, to determine the possible
effect of the temperature on the size and surface charge of
AZI-liposomes, the experiments were also conducted at 25°C.
The results presented in Table 3 demonstrate signiﬁcant
increase (t-test, p<0.05) in mean diameters of all AZI-lipo-
somes because of their interaction with vaginal ﬂuid
Table 2 Size and surface characteristics of the AZI-liposomes
Liposomes Originally prepared Extruded (3x400 nm) Zeta potential (mV)
Mean diameter (nm) PDI Mean diameter (nm) PDI
CL-1 351±3 0.27±0.02 259±1* 0.17±0.01* −66.4±1.3
CL-2 840±11 0.63±0.08 221±2* 0.26±0.10* −21.6±0.6
CL-3 466±3 0.24±0.03 262±3* 0.18±0.03 −61.5±0.7
PGL-1 545±14 0.56±0.01 341±27#* 0.74±0.08* −18.2±0.5
PGL-2 529±10 0.24±0.01 222±2* 0.20±0.02* −55.8±0.9
DPGL-1 574±8 0.49±0.09 219±1* 0.27±0.01* −17.8±0.6
DPGL-2 287±3 0.31±0.01 189±1* 0.22±0.02* −53.1±0.5
Notes: The values are the mean ± S.D.; n=3 (mean diameter, PDI); n=5 (zeta potential); #Estimated size due to high PDI value (>0.7). *Statistically signiﬁcant compared to
the originally prepared liposomes (t-test, p<0.05).
Abbreviation: PDI, polydispersity index.
Table 3 Characteristics of the AZI-liposomes at simulated vaginal conditions
Liposomes Mean diameter (nm) PDI Zeta potential (mV)
CL-1 276±5a 0.19±0.02a −0.6±0.3a
270±3b 0.20±0.02b −0.4±0.1b
CL-2 392±24a 0.46±0.08a 4.1±0.4a
397±12b 0.42±0.10b 4.4±0.3b
CL-3 323±4a 0.22±0.02a −4.4±0.3a
331±3b 0.21±0.09b −4.2±0.3b
PGL-1 382±7a 0.77±0.09a 4.4±0.3a
389±9b 0.73±0.08b 5.1±0.4b
PGL-2 274±4a 0.15±0.03a −1.8±0.3 a
276±3b 0.17±0.08b −2.1±0.1b
DPGL-1 262±5a 0.21±0.10a 3.8±0.3a
258±3b 0.22±0.05b 4.6±0.2b
DPGL-2 217±2a 0.19±0.05a −1.6±0.2a
212±3b 0.20±0.03b −2.9±0.2b
Notes: a37°C; b25°C. The extruded AZI-liposomes were dispersed in VFS, pH 4.5, and the mean diameters, PDIs and zeta potentials were determined at 37°C. The
measurements were also performed at 25°C to investigate the effect of temperature on the physical properties of liposomes. The each value represents the mean ± S.D.
(n=3, mean diameter, PDI; n=5, zeta potential). Signiﬁcant differences between the determined parameters were not obtained when experiments were carried out at 25 or
37°C (t-test, p>0.05).
Abbreviation: PDI, polydispersity index.
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components, in comparison to the corresponding values shown
in Table 2. However, polydispersity indexes commonly
remained unchanged despite of the used media (buffer, pH
7.5 or VFS, pH 4.5), except for the CL-2 and PGL-1.
Similarly as the mean diameters, the zeta potentials of
AZI-liposomes (Table 2) have signiﬁcantly changed (t-test,
p<0.05) at mimicked vaginal conditions (Table 3). The origin-
ally, highly negative zeta potentials of CL-1, CL-3, PGL-2 and
DPGL-2 decreased from approximately −50 mV (buffer, pH
7.5) to −4 mV (VFS, pH 4.5), while AZI-liposomes with
slightly negative surface charge (between −18 and −21 mV)
changed to slightly positive values (4 mV). Interestingly, the
temperature did not affect the size and surface properties of the
liposomes (t-test, p>0.05).
Since the cervical tissue is characterized by neutral pH33
and considering the fact that the temperature had no impact
on the physical properties of liposomes (Table 3), the physi-
cal properties of AZI-liposomes shown in Table 2 (obtained
in the buffer, pH 7.5) could be translated to mimicked cervi-
cal conditions.
The thermodynamic state of the liposome bilayers is
responsible for their release pattern and permeation ability,
as well as the interactions of liposomes with bacteria and
bioﬁlms.17,23,34 Liposome bilayer elasticity/rigidity was eval-
uated by applying an easy and reproducible method based on
the passage of liposomes through 100-nm membranes under a
constant external pressure (2.5 bar) for 5 min.22 The results
presented in Table 4 conﬁrmed that PGLs and DPGLs are
elastic liposomes, while CLs, particularly CL-2 and CL-3,
exhibited pronounced rigid bilayers. In addition, the degree
of bilayer elasticity (E) was conﬁrmed to be commonly depen-
dent on the quantity of extruded liposomes (J) rather than their
size following extrusion (rv) through 100-nm membranes (rp).
Comparison of the calculated E values among the different
CLs showed the lowest elasticity for CL-2 and CL-3 due to the
presence of 25% (w/w) hydrogenated soybean phosphatidyl-
choline (SPC-3) in the bilayers. In contrast, PGLs and DPGLs
were characterized by ﬂexible bilayers with E values between
12 and 17, whereas the elasticity of PGLs was somewhat less
pronounced. The highest E value was conﬁrmed for DPGL-2
(ANOVA, p<0.05), with a value almost 34-fold higher than the
E values of CL-2 and CL-3. The increased elasticity of DPGLs
compared with PGLs is ascribed to the presence of 15% (w/w)
monoacyl phosphatidylcholine in DPGLs. These results are in
accordance with previously published ﬁndings for DPGLs
containing the same ratio of propylene glycol but with sodium
deoxycholate as an edge activator.22
Properly balancing physical characteristics enables the
development of liposomes with suitable encapsulation of
AZI as a prerequisite for adequate therapeutic outcomes.
Table 4 Liposome bilayer elasticity
Liposomes J (g) rv (nm) E
CL-1 1.61±0.2 165±2 4.4±0.3*
CL-2 0.17±0.0 185±3 0.58±0.1
CL-3 0.19±0.1 165±2 0.52±0.2
PGL-1 4.26±0.3 178±1 13.53±0.3*
PGL-2 4.41±0.2 169±2 12.64±0.2*
DPGL-1 6.63±0.4 154±2 15.70±0.4*
DPGL-2 7.91±0.3 147±1 17.02±0.3*
Notes: The values are the mean ± S.D. (n=3). One-way ANOVA and Tukey’s
multiple comparison test, with p<0.05 set as the minimal level of signiﬁcance,
were applied for comparison of the E values. *Statistically signiﬁcant compared to
CL-2 and CL-3 (p<0.05).
Abbreviations: E, degree of liposome bilayers elasticity; J, amount of extruded
liposomes; rv, average diameter of liposomes following extrusion under constant
pressure.
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Since our aim was topical vaginal therapy, liposomes with
diameters of 200–300 nm are expected to be optimal.35
As shown in Figure 1, encapsulation of AZI differed
between 29% (4.4 µg AZI/mg lipid) for CL-2 and 55%
(8.3 µg AZI/mg lipid) for DPGL-1. These results are a con-
sequence of the physicochemical properties of AZI and the
liposomal constituents, both affecting encapsulation of the
drug. AZI, even in the form of dihydrate, exhibits lipophilic
features (log P=3.98),13 therefore it is expected to become
accommodated within the liposome bilayers. However, mole-
cular weight of AZI is rather large (Mw 785),13 restricting its
incorporation within bilayers. The differences in the encapsu-
lation efﬁciencies observed between the various types of lipo-
somes thus proceed from the effects of the liposomal
constituents on AZI incorporation. Generally, liposomes with
EPG embedded as a bilayer constituent were able to incorpo-
rate signiﬁcantly larger amounts of the drug (except for
DPGL-2) than the corresponding liposomes composed of
only neutral phospholipids (t-test, p<0.05). Such results are
probably a consequence of the interaction between AZI and
the negatively charged EPG inside liposome bilayers, facilitat-
ing the encapsulation of AZI. Binding of AZI to negatively
charged phospholipids has been conﬁrmed by Van Bambeke
et al36. Among the various negatively surface-charged lipo-
somes (CL-1, CL-3, PGL-2 and DPGL-2), both types of
elastic liposomes (PGL-2 and DPGL-2) demonstrated signiﬁ-
cantly higher encapsulation efﬁciency than CL-1 and CL-3
(ANOVA, p<0.05). Increased incorporation of AZI in the
elastic liposomes was due to the presence of propylene glycol
(PGLs, DPGLs) and the monoacyl phospholipid SLPC-80
(DPGLs), which both facilitate solubilization and hence
improve encapsulation of AZI. Contrary to the previous ﬁnd-
ings obtained for deformable liposomes,17,21,23 DPGLs exhib-
ited superior drug encapsulation because the presence of
monoacyl phosphatidylcholine increased the solubilization of
AZI. Namely, monoacyl phospholipid has been proven as a
more efﬁcient solubilizer than diacyl phospholipid.37 The
slightly lower encapsulation of AZI in DPGL-2 than in
DPGL-1 could be attributed to the possible interaction/com-
petition of the monoacyl phospholipid and the negatively
charged phospholipid inside the bilayers of DPGL-2 for
AZI; however, further studies, such as Fourier transform infra-
red spectroscopy (FT-IR), are necessary to prove the interac-
tions of liposomal bilayer constituents and the drug.
In vitro release studies
The predictable release of the encapsulated drug from
liposomes in medium simulating the in vivo environment
is of great signiﬁcance regarding the use of liposomes as
drug delivery nanosystems. As the human vaginal mucosa
has a pH between pH 4 and 5, studies were performed in
conditions simulating the vaginal environment, ie, VFS,
pH 4.5. The experiments were also performed in PBS, pH
7.5, to mimic cervical conditions,33 and to investigate the
effect of pH and vaginal ﬂuid components on AZI release
from the liposomes.
The results in Figure 2 demonstrate the prolonged
release of AZI from all the liposomes in both tested media
relative to the control (AZI solution) (ANOVA, p<0.05).
Overall, the release from all the tested liposomes was
slightly increased when the liposomes were dispersed in
VFS, pH 4.5, than in PBS, pH 7.5, as a result of the effects
of lower pH and vaginal ﬂuid components on liposome
stability.38 Despite the used release media, all the liposomes
exhibited initial burst release followed by sustained AZI
release. Such a release proﬁle might be relevant for facil-
itating the rapid start of antibiotic activity and ensuring
increased local drug concentrations.
Liposome membrane elasticity/rigidity signiﬁcantly
inﬂuenced the AZI release proﬁle from the different
liposomes under simulated cervicovaginal conditions.
Thus, the slowest release, at both pH 4.5 and 7.5, was
obtained from the rigid liposomes, ie, CL-2 and CL-3,
followed by less rigid CL-1, while AZI release was
signiﬁcantly faster from both types of elastic liposomes.
For instance, 70–80% of the originally encapsulated AZI
was released after 6 h from PGLs and DPGLs under
simulated vaginal conditions, compared to 40–45% with
CL-2 and CL-3. Increased AZI release from PGLs, espe-
cially from DPGLs, was expected due to the increased
membrane permeability caused by propylene glycol
(PGLs) in addition to intercalation of the edge activator
(SLPC-80) in bilayers of DPGLs. These observations are
in accordance with previous reports for PGLs and
DPGLs.17,22,39 In addition to bilayer elasticity, the highly
negative surface charge also increased the release of AZI.
Similar behavior of negatively charged liposomes was
also observed by Pavelić et al38. However, this effect
was negligible in comparison to the impact of membrane
elasticity (Figure 2).
Storage stability studies
The stability of liposomes during storage is an important
feature considering their use as drug nanoformulations. As
shown in Figure 3, all the liposomes with slightly negative
surface charges (CL-2, PGL-1, and DPGL-1) signiﬁcantly
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increased in size (mean diameters and PDIs) during storage in
comparison to the corresponding initial values; CL-2 and
DPGL-1 increased after 2 months (CL-2 from 221 to
267 nm and DPGL-1 from 248 to 274 nm), while PGL-1
increased after 5months (from341 to 372 nm) (t-test, p<0.05)
(Figure 3A and B). The lower physical stabilities of CL-2 and
DPGL-1 were closely associated with their slightly negative
surface charges (−20 and −18 mV, Figure 3C). In addition,
DPGL-1 was characterized by the signiﬁcantly pronounced
membrane elasticity (15.7, Table 3), making their bilayers
more permeable and prone to aggregation (fusion). These
observations are consistent with the recently reported ﬁnd-
ings demonstrating the inﬂuence of the bilayer elasticity on
the reduced physical stability of liposomes incorporating
lipophilic drug.17 In contrast, the liposomes with highly
negative surface charge (zeta potentials between −50 and
−60 mV), namely, CL-1, CL-3, PGL-2 and DPGL-2, were
physically stable during 7 months of storage (Figure 3C).
Similar ﬁndings were previously reported by Palac et al,21
whereas highly negatively surface charged elastic and rigid
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Figure 2 In vitro AZI release from the different types of liposomes.
Notes: The each value represents the mean ± S.D. (n=3). One-way ANOVA and Tukey’s multiple comparison test, with p<0.05 set as the minimal level of signiﬁcance, were
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liposomes with encapsulated hydrophilic drug remained phy-
sically stable over 10 months of storage at 4°C.
A comparison of the two different preparations of
highly negatively charged CLs (CL-1 and CL-3) showed
similar stability proﬁles. Since the bilayers of CL-3 were
signiﬁcantly more rigid than those of CL-1 (Table 3), it is
assumed that CL-3 will be more suitable for further studies
due to the lower possibility of drug leakage.
Finally, taking into account the physical characteristics of
the liposomes, suitable AZI encapsulation, in vitro AZI release
patterns under simulated cervicovaginal conditions and sto-
rage stability, CL-3, PGL-2 and DPGL-2 were selected for
further investigations. Their composition is schematically
depicted by Figure 4. Besides phosphatidylcholine (major
phospholipid) and 5% phosphatidylglycerol (negatively
charged lipid) common for all optimized liposomes (CL-3,
PGL-2 and DPGL-2), the bilayers of CL-3 were enriched with
hydrogenated phosphatidylcholine (SPC-3) contributing to
membrane rigidity. On the other hand, elastic liposomes
embedded either propylene glycol (PGL-2) or both propylene
glycol andmonoacyl phospholipid (DPGL-2) in their bilayers,
decreasing bilayers’ compactness, while increasing its
elasticity.
Ex vivo permeation studies
Localized antimicrobial therapy has been used to treat
vaginal infections. However, its efﬁciency is frequently
reduced because of several factors. For instance, possible
systemic drug absorption and drug teratogenicity (metroni-
dazole) can take place, and inadequate local drug concen-
trations may be achieved, along with the possible
development of antibiotic-resistant strains, the formation
of bioﬁlms and the failure of the drugs to reach the desired
site of action. These possibilities make oral administration
of high doses of antibiotics necessary, which may lead to an
increased incidence of undesired drug side effects, patient
inconvenience and an enhanced risk of antibiotic resistance
development.40
The use of liposomes represents a suitable approach to
achieve effective localized vaginal therapy. Manipulation
of the physical characteristics of liposomes (bilayer elas-
ticity/rigidity, surface coating) enables the delivery of
encapsulated drugs to the site of action.10 Therefore, to
more closely resemble the applicability of AZI-liposomes
for the treatment of vaginal infections, ex vivo permeation
studies were performed.
The results presented in Figure 5 refer to AZI levels
determined in the acceptor chamber (penetrated AZI), within
vaginal tissue, and on the vaginal surface (nonpenetrated AZI)
after 24 h of testing. It was not possible to detect the presence
of AZI in the acceptor chamber during the ﬁrst 6 h of testing
since the drug content was under the limit of detection. The
only exception was the control (free AZI), for which a negli-
gible amount of the drug was detected after 5 h.
The performed ex vivo studies undoubtedly demonstrate
the potential of AZI-liposomes in localized vaginal therapy
(Figure 5). All tested liposomes enabled accumulation of the
drug on the vaginal surface (17–24%) and mostly inside
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vaginal tissue (57–63%), generating higher local concentra-
tions of AZI and reducing its undesired penetration to the
systemic circulation compared to the control (free AZI).
Increased retention of the drug inside the vagina could be
relevant for the treatment of recurrent bacterial vaginosis and
bioﬁlm-related infections. Comparison of the different types
of liposomes demonstrated the highest penetration ability for
DPGL-2, followed by PGL-2 and CL-3 (Figure 5). These
ﬁndings are consistent with the bilayer properties of lipo-
somes (Table 3) inﬂuencing AZI deposition/penetration in
vaginal tissue. For instance, CL-3 had rigid bilayers facilitat-
ing retention of the AZI on/within the vaginal tissue. In
contrast, the highest AZI penetration was observed with
DPGL-2 (Figure 5), which is in accordance with its very
elastic bilayers, facilitating increased drug penetration into/
through the vaginal tissue.
The physicochemical properties of liposomes signiﬁcantly
contribute to the vaginal deposition/penetration abilities of the
encapsulated drug. Thus, mucoadhesive, chitosan-coated lipo-
somes enabled the localization of clotrimazole on the vaginal
surface,41 while non-mucoadhesive, ie, mucus-penetrating,
PEGylated liposomes demonstrated increased interferon
alpha penetration into/through the vaginal mucosa,42 in com-
parison to controls (solutions of the free drugs at the same
CL-3 PGL-2 DPGL-2
Elastic liposomesConventional liposomes
Phosphatidylcholine
Hydrogenated Phosphatidylcholine
Phosphatidylglycerol
Monoacyl Phosphatidylcholine
Propylene glycol
Azithromycin
Figure 4 Schematic drawing of the AZI-liposomes explored for ex vivo vaginal deposition/penetration, in vitro antibacterial activity and biocompatibility studies.
70
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In tissue
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20
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0
Figure 5 Ex vivo deposition/penetration of AZI into/through porcine vaginal tissue.
Notes: The each value represents the mean ± S.D. (n=3). One-way ANOVA and Tukey’s multiple comparison test, with p<0.05 set as the minimal level of signiﬁcance, were
applied for comparison of the levels of nonpenetrated, penetrated and AZI retained in the tissue, from different types of AZI-liposomes and control. *Signiﬁcantly different
(ANOVA, p<0.05) from free AZI (control). **Signiﬁcantly different (ANOVA, p<0.05) from CL-3.
Abbreviation: AZI, azithromycin.
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concentrations present in the tested liposomes). In a recent
study, positively charged liposomeswith rigid bilayers enabled
localization of AZI on the skin surface due to strong interac-
tions with the negatively charged skin cells.17
In vitro antibacterial activity
The optimized AZI-liposomes (CL-3, PGL-2 and DPGL-
2) were investigated for their in vitro antibacterial activity
against several bioﬁlm-forming and planktonic E. coli
strains (Tables 5 and 6) and against intracellular C. tra-
chomatis (Figure 6).
The results for planktonic E. coli are expressed asMIC50
values, while those obtained for the pre-exposure mode of
the bioﬁlm assay are presented as IC50 values (Table 5).
As shown in Table 5, the antibacterial activity of all the
AZI samples (both liposomally encapsulated and free AZI)
varied among the strains. In general, E. coli K-12 was the
most sensitive to AZI, followed by E. coli ATCC 700928
and ATCC 8739. All the AZI-liposomes were more effec-
tive than the free AZI against E. coli ATCC 700928, with
MIC50 values approximately 3-fold lower than the MIC50
of the free AZI. A comparison of the activities achieved by
the different types of liposomes toward E. coli K-12
demonstrated the similar efﬁcacy of CL-3 and PGL-2,
while the activity of DPGL-2 was signiﬁcantly lower
(ANOVA, p<0.05). Regarding E. coli ATCC 8739, all of
the AZI-liposomes demonstrated activity similar to that of
the free antibiotic; CL-3 exhibited slightly lower activity,
but this activity was not signiﬁcantly different from that of
free AZI (t-test; p>0.05).
Similarly, the observed anti-bioﬁlm activity of the AZI-
liposomes varied between strains. For example, CL-3 was
the most effective against E. coli ATCC 700928 and K-12,
exhibiting IC50 values almost 8-fold lower than those of the
free antibiotic. PGL-2 and DPGL-2 demonstrated lower
anti-bioﬁlm activity than CL-3 (ANOVA, p<0.05), but this
activity was still signiﬁcantly stronger than that of the free
AZI (t-test, p<0.05). PGL-2 inhibited E. coli ATCC 8739
bioﬁlm formation with an IC50 of 6.36 µg/ml, which was
twice as low as the IC50 of the free AZI (Table 5). By
contrast, CL-3 and DPGL-2 displayed weaker anti-bioﬁlm
activity (Table 5).
The observed variability in the activity of the different
types of AZI-liposomes tested might be a consequence of the
bilayer properties of the tested liposomes affectingAZI release
and the susceptibility of the different E. coli strains to AZI.
CL-3 contained hydrogenated phospholipids in the bilayers,
contributing to a higher phase transition temperature,43 Ta
b
le
5
A
nt
im
ic
ro
bi
al
ac
tiv
ity
of
A
Z
I-l
ip
os
om
es
ag
ai
ns
t
pl
an
kt
on
ic
ba
ct
er
ia
an
d
bi
oﬁ
lm
s
in
th
e
pr
e-
ex
po
su
re
m
od
e
of
th
e
as
sa
y,
as
m
ea
su
re
d
by
tu
rb
id
ity
m
ea
su
re
m
en
ts
an
d
re
sa
zu
ri
n
st
ai
ni
ng
,r
es
pe
ct
iv
el
y
S
am
p
le
M
IC
5
0
(µ
g/
m
l)
(9
5%
co
n
ﬁ
d
en
ce
in
te
rv
al
s)
IC
5
0
(µ
g/
m
l)
(9
5%
co
n
ﬁ
d
en
ce
in
te
rv
al
s)
P
la
n
kt
o
n
ic
b
ac
te
ri
a
P
re
ve
n
ti
o
n
o
f
b
io
ﬁ
lm
fo
rm
at
io
n
E
.
co
li
A
T
C
C
87
39
E
.
co
li
A
T
C
C
70
09
28
E
.
co
li
K
-1
2
E
.
co
li
A
T
C
C
87
39
E
.
co
li
A
T
C
C
70
09
28
E
.
co
li
K
-1
2
F
re
e
A
Z
I
7.
50
(5
.8
9–
9.
56
)
7.
51
(6
.6
6–
8.
47
)
2.
76
(1
.5
7–
4.
82
)
14
.0
8
(1
2.
76
–
21
.0
5)
21
.0
9
(1
9.
16
–
23
.2
9)
10
.0
1
(8
.7
9–
12
.2
1)
C
L
-3
8.
42
(5
.9
0–
9.
56
)
2.
48
(1
.9
5–
3.
14
)
1.
66
(1
.5
4–
2.
31
)
45
.6
5
(4
0.
23
–
55
.2
7)
2.
70
(2
.1
1–
4.
04
)
1.
26
(1
.1
3–
1.
85
)
P
G
L
-2
7.
38
(4
.6
2–
11
.8
1)
2.
31
(1
.6
2–
3.
29
)
1.
26
(0
.6
6–
1.
74
)
6.
36
(5
.4
6–
10
.4
6)
12
.1
5
(1
1.
03
–
14
.2
2)
3.
49
(1
.8
7–
6.
55
)
D
P
G
L
-2
7.
66
(6
.9
7–
10
.7
9)
2.
49
(1
.6
9–
3.
68
)
2.
61
(1
.5
9–
4.
27
)
26
.6
5
(2
4.
56
–
36
.5
1)
11
.2
4
(7
.7
9–
16
.2
3)
6.
10
(4
.4
7–
8.
32
)
A
b
b
re
vi
at
io
n
s:
IC
50
,h
al
f-m
ax
im
al
in
hi
bi
to
ry
co
nc
en
tr
at
io
n;
M
IC
50
,c
on
ce
nt
ra
tio
n
of
th
e
an
tib
io
tic
th
at
in
hi
bi
te
d
ba
ct
er
ia
lg
ro
w
th
by
50
%
.
Dovepress Vanić et al
International Journal of Nanomedicine 2019:14 submit your manuscript | www.dovepress.com
DovePress
5969
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
21
4.
16
5.
38
 o
n 
15
-A
ug
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
allowing slower AZI release, which could be relevant for
preventing bioﬁlm formation by E. coli ATCC 700928 and
K-12.
To examine the potential of AZI-liposomes to eradicate
preformed E. coli bioﬁlms, the bioﬁlms were exposed to AZI
samples (both liposomally encapsulated and the free drug).
As shown in Table 6, the strongest inhibition of theE. coli
bioﬁlms was achieved with DPGL-2, even though this for-
mulation showed lower activities than CL-3 and PGL-2
against planktonic E. coli and toward the suppression of
bioﬁlm formation (pre-exposure mode). DPGL-2 inhibited
E. coli ATCC 700928 bioﬁlm viability by 46% compared
with the 27% and 26% inhibition obtained with PGL-2 and
the free AZI, respectively. However, its anti-bioﬁlm activity
varied between strains. The strongest inhibition (ANOVA,
p<0.05) was obtained against E. coliATCC 700928 bioﬁlms,
followed by E. coli K-12 and E. coli ATCC 8739 bioﬁlms
(Table 6). When tested against E. coli ATCC 8739, PGL-2
was the most active among the different AZI-liposomes
(27% inhibition), but it was not signiﬁcantly more active
versus DPGL-2 (25% inhibition, ANOVA, p>0.05).
However, PGL-2 displayed signiﬁcantly enhanced activity
compared to the free antibiotic (17%), while the anti-bioﬁlm
activity of CL-3 was similar to that of the free drug (Table 6).
Overall, anti-bioﬁlm activity (Table 6) was lower than in
the pre-exposure mode of the assay (Table 5). These ﬁnd-
ings are in agreement with the well-known fact that eradi-
cation of bacterial bioﬁlms is difﬁcult to achieve, even with
Table 6 Eradication of E. coli bioﬁlms at the highest tested concentration (78.50 µg/ml) in the postexposure mode of the assay, as
measured using a resazurin staining assay
Sample Inhibition of bioﬁlm viability (%)
E. coli ATCC 8739 E. coli ATCC 700928 E. coli K-12
Free AZI 17.49±1.54 26.44±7.14 26.88±6.00
CL-3 16.44±2.31 25.15±4.83 26.95±3.06
PGL-2 26.94±1.86 27.15±5.09 30.31±1.55
DPGL-2 25.24±14.01 45.67±7.14* 38.08±13.74**
Notes: The values indicate the mean ± S.D. (n=4). *Statistically signiﬁcant compared to free AZI, PGL-2 and CL-3 (ANOVA, p<0.05). **Statistically signiﬁcant compared to
free AZI, PGL-2 and CL-3 (ANOVA, p<0.05).
Abbreviation: AZI, azithromycin.
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Figure 6 In vitro activities of AZI-liposomes against C. trachomatis presented as MIC values.
Notes: C. trachomatis (MOI 0.2)-infected HeLa cells were cultured in the presence of 0.5–0.0002 μg/ml free or liposomally loaded AZI (CL-3, PGL-2 and DPGL-2). C.
trachomatis genome concentrations were measured at 48 h post infection by direct qPCR. Data are presented as the mean Ct levels ± S.D. (n=3).
Abbreviations: AZI, azithromycin; Ct, cycle threshold; MIC, minimum inhibitory concentration; qPCR, quantitative polymerase chain reaction.
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the application of very high concentrations of antibiotics.44
The enhanced activities of elastic liposomes, particularly
DPGL-2 against E. coli bioﬁlms, were probably a conse-
quence of the bilayer properties of the elastic liposomes,
which permit their enhanced penetration into the formed
bioﬁlms. Additionally, the presence of monoacyl phospha-
tidylcholine in DPGL-2 has been shown to increase anti-
bioﬁlm activity.
A limited number of studies reported on the efﬁcacy of
liposomal antibiotics against planktonic E. coli, but none
examined activity against E. coli bioﬁlms. According to a
literature search, only so-called fusogenic liposomes
encapsulating tobramycin or vancomycin have been exam-
ined against planktonic E. coli.45,46 Their superior activ-
ities in comparison to the free antibiotics were considered
a result of the conﬁrmed fusion of the vesicles composed
of dioleoyl phosphatidylethanolamine, dipalmitoyl phos-
phatidylcholine and cholesteryl hemisuccinate (4:2:4,
molar ratio) with E. coli, allowing release of the encapsu-
lated vancomycin in the cytoplasm of E. coli.46
The obtained data for in vitro antibacterial activity
(Tables 5 and 6) are important regarding the potential
use of AZI-liposomes in localized vaginal therapy for E.
coli infections. CL-3 and PGL-2 would have potential for
the treatment of superﬁcial infections caused by planktonic
E. coli and the prevention of complicated infections, while
DPGL-2 seems the most promising among the tested lipo-
somes for the treatment of bioﬁlm-related infections. The
AZI-liposomes with elastic bilayers exhibited enhanced
antibacterial activities against Staphylococcus aureus and
MRSA clinical isolates,17 which is of great relevance
considering the possible use of AZI-liposomes for the
treatment of aerobic vaginitis caused by both E. coli and
S. aureus. Cervicovaginal infections caused by S. aureus
have also been reported to increase the risk of fetal com-
plications in pregnant women, similar to E. coli.47 In the
present study, all AZI-liposomes were negatively charged,
which could be signiﬁcant regarding the biocompatibility
issue. Interestingly, the negative surface charge has also
been shown to inﬂuence the antimicrobial efﬁcacy of AZI-
liposomes toward M. avium, as demonstrated by Oh et
al16. Since AZI is a potent broad-spectrum antibiotic, we
assume that AZI-liposomes could be suitable for the treat-
ment of recurrent bacterial vaginosis caused by bacteria
other than E. coli and S. aureus, based on the reported
efﬁcacy of AZI against Gardnerella vaginalis, Atopobium
vaginae, Bacteroides spp., Mobiluncus spp. and
Mycoplasma spp.48,49 Moreover, high doses of AZI are
recommended as the ﬁrst choice of therapy for the treat-
ment of A. vaginae and G. vaginalis bacterial vaginosis to
prevent preterm birth.50 Therefore, it seems reasonable to
broaden the possible applicability of AZI-liposomes for
the treatment of recurrent bacterial vaginosis; however,
the efﬁcacy of the developed liposomes has to be investi-
gated to prove these assumptions.
In addition to E. coli, the AZI-liposomes were also
tested against intracellular C. trachomatis. A direct qPCR
method was applied to determine the MICs of the free AZI
and the liposomally loaded AZI (CL-3, PGL-2, and
DPGL-2). C. trachomatis (MOI 0.2)-infected HeLa cells
were cultured in the presence of 0.5–0.0002 µg/ml AZI
samples, and the dose-response curves were evaluated
48 h post infection (Figure 6). The MIC values were
identiﬁed by statistical comparison of the bacterial DNA
concentrations (Ct values) measured in the presence of a
given AZI concentration with the Ct values of bacterial
DNA in the presence of the highest AZI concentration.
The Ct levels measured in the presence of the highest
antibiotic concentrations were considered as the genome
concentration of the inoculum. The MIC value was deﬁned
as the lowest AZI concentration, where the Ct values were
not signiﬁcantly different from the inoculum.28
Among the different types of AZI-liposomes tested against
C. trachomatis, DPGL-2 was the most effective, with MIC
value of 0.0312 μg/ml, followed by PGL-2 (0.0625 μg/ml) and
CL-3 (0.125 μg/ml) (Figure 6). These results correlate with the
bilayer elasticity/rigidity of the examined liposomes (Table 4),
leading to more rapid AZI release from DPGL-2 than CL-3
(Figure 2). The lower efﬁcacy of all the AZI-liposomes than
the control (free AZI) could be a consequence of the fact that
C. trachomatis is an intracellular pathogen and that lipophilic
AZI in solution form is more easily taken up by the cells than
liposomes,51,52 which was also conﬁrmed by ex vivo penetra-
tion studies (Figure 5), showing higher penetration of free AZI
through the vaginal tissue. On the other hand, the surface
charge of the liposomes also plays an important role in the
internalization of the encapsulated drug. Generally, positively
surface-charged (cationic) liposomes allow fusion with nega-
tively surface-charged epithelial cells, enabling efﬁcient intra-
cellular drug delivery.8 Since all the tested liposomes in this
study were negatively surface charged, it is assumed that they
exhibited lower afﬁnity toward HeLa cells than the free drug,
which is supported by Sangaré and collaborators,53 who
demonstrated that cationic liposomes encapsulating doxycy-
cline were 2-fold more effective than free doxycycline against
C. trachomatis in vitro. Therefore, the efﬁcacy of the
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positively surface-charged AZI-liposomes against C. tracho-
matis would be worthy to evaluate in future investigations.
Considering that the impact of antimicrobials on chlamy-
dial growth was evaluated by direct qPCRwith unpuriﬁed cell
lysates, we measured the impact of the unpuriﬁed cell lysates
on the performance of qPCR (Figure 7). Namely, it should be
excluded whether the tested samples (AZI-liposomes and free
AZI) had a direct inhibitory or stimulatory effect on the qPCR,
inﬂuencing the dose-response curves of the AZI samples
(AZI-liposomes and free AZI). To test this possible effect,
Chlamydia-speciﬁc qPCRs were performed in the presence
and absence of AZI (AZI-liposomes and free AZI). For that
purpose, C. trachomatis-infected HeLa cell lysates were
mixed with uninfected but AZI-treated (AZI-liposomes or
free AZI) HeLa cell lysates. The ﬁnal concentration of AZI
was the highest concentration applied in the chlamydial
growth inhibition experiments. Before cell lysis, similar to
the dose-response curve experiments, the medium was
removed, and the cells were washed with PBS. As a control,
C. trachomatis-infected HeLa cell lysates were mixed with
uninfected and AZI untreated HeLa cell lysates. If the AZI
samples had no impact on the qPCR, then the AZI-containing
samples had Ct levels similar to the Ct levels of the control.
The results presented in Figure 7 show that the
detected chlamydial genome concentrations (Ct levels) of
AZI samples (liposomes and the free drug) and the sample
without AZI (control) were not signiﬁcantly different (t-
test; p>0.05). Consequently, qPCR measurement of
chlamydial growth inhibition was not inﬂuenced by the
applied compounds.
Biocompatibility studies
The biocompatibility of AZI-liposomes (CL-3, PGL-2 and
DPGL-2) was investigated in vitro to determine the possi-
ble cytotoxic effects of the liposome constituents and AZI
toward human cervical cells (HeLa cells). It was reported
that AZI can synergistically enhance the antiproliferative
activity of vincristine in cancer cells.54 Furthermore,
recent ﬁndings demonstrated that free AZI was cytotoxic
to human ﬁbroblasts at a concentration of 16 µg/ml (49%
viability) and human keratinocytes at 64 µg AZI/ml (55%
viability), while entrapment of AZI in liposomes signiﬁ-
cantly decreased skin cell cytotoxicity.17
The performed studies showed that all AZI-liposomes
were compatible with the HeLa cells (Figure 8A). Even at
the highest tested concentration (39.25 µg/ml), the viabi-
lity of the cells remained above 70%, which is considered
a noncytotoxic threshold.55 Comparison of the different
types of AZI-liposomes proved CL-3 to be the most com-
patible, while the HeLa cells were more sensitive to both
types of elastic liposomes, particularly DPGL-2, at the
highest tested AZI concentration, which covered and
exceeded the MIC50 and IC50 values for E. coli and sig-
niﬁcantly surpassed the MIC values for C. trachomatis.
Evaluation of the empty liposomes (without encap-
sulated AZI) at concentrations that corresponded to
AZI-liposomes proved the biocompatibility of all tested
liposomes (Figure 8B). Therefore, the slightly increased
sensitivity of the HeLa cells toward elastic AZI-lipo-
somes (PGL-2, DPGL-2) (Figure 8A) is thought to be a
result of the increased AZI release from the elastic
liposomes (Figure 2), facilitated by the presence of
10% propylene glycol in dispersions of PGL-2 and
DPGL-2, in addition to 15% monoacyl phosphatidylcho-
line inside the bilayers of DPGL-2 (Table 1). These
assumptions are supported by recent ﬁndings demon-
strating the sensitivity of human keratinocytes and ﬁbro-
blasts to deformable liposomes, which was also affected
by increased drug release and the presence of an edge
activator (sodium deoxycholate).17
Although monoacyl phospholipids (lysophospholipids)
have been proven to contribute to cell cytotoxicity at
concentrations >50 µg/ml,56 in this study the concentration
of monoacyl phosphatidylcholine in DPGL-2 was signiﬁ-
cantly lower (39 µg/ml at the highest tested concentration),
and the exposure time was 24 h in comparison to 72 h.56
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Figure 7 Estimation of the impact of AZI-liposomes and free AZI on qPCR.
Notes: Chlamydia-speciﬁc qPCRs were performed in the presence of AZI-lipo-
somes and free AZI at the highest applied concentrations that were used in the
dose-response curve measurement experiments. One-way ANOVA and Tukey’s
multiple comparison test, with p<0.05 set as the minimal level of signiﬁcance,
were applied for comparison of qPCR Ct levels of CL-3, PGL-2, DPGL-2 and free
AZI containing samples and control. No signiﬁcant differences were found (p>0.05).
Data are presented as the mean Ct value ± S.D. (n=3).
Abbreviations: AZI, azithromycin; Ct, cycle threshold; qPCR, quantitative poly-
merase chain reaction.
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Hence, monoacyl phosphatidylcholine did not contribute
to the cytotoxic effects of DPGL-2 under the applied
conditions, even though there was a general trend of
lower cell viability at higher AZI concentrations in
DPGL-2 (Figure 8A). However, the possible cytotoxicity
of DPGL-2 might be expected at higher concentrations of
monoacyl phospholipid and with longer exposure of
DPGL-2 to cervical cells (72 h).
The biocompatibility of the liposomes examined in this
research could also be a consequence of their negative
surface charge. Namely, cationic liposomes incorporating
dimethyldioctadecyl ammonium bromide applied at higher
concentrations signiﬁcantly decreased the viability of
A549 human lung cells and ﬁbroblasts,17,57 in comparison
to the corresponding negatively charged liposomes.
Conclusion
The results of all the performed studies indicate that targeting
cervicovaginal infections requires careful tailoring of the
liposomal characteristics to yield stable liposomes that are
biocompatible with cervical cells, allowing sustained AZI
release and localization within vaginal tissue while enhan-
cing antibacterial activity. The selection of AZI-liposomes
should be based on the targeted bacterial strain. CL-3 would
be optimal for preventing E. coli 700928 and K12 bioﬁlms,
while PGL-2 would be optimal for inhibiting the formation
of E. coli 8739 bioﬁlms. DPGL-2 exhibited the strongest
potential for the eradication of E. coli bioﬁlms and was the
most promising among the examined liposomes toward C.
trachomatis. Further formulation development should focus
on ensuring the prolonged residence time of AZI-liposomes
in the vaginal cavity by inclusion in a secondary vehicle, such
as a mucoadhesive hydrogel.
Abbreviation list
AZI, azithromycin; CFU, colony forming units; CLs, conven-
tional liposomes; Ct, cycle threshold; DPGLs, deformable
propylene glycol liposomes; E, degree of liposome membrane
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used to dissolve free AZI (B).
Note: The presented values are the mean ± S.D. (n=3).
Abbreviation: AZI, azithromycin.
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elasticity; EPC, egg phosphatidylcholine, EPG, egg phospha-
tidylglycerol sodium salt; IC50, half-maximal inhibitory con-
centration; J, mass of extruded liposomes in elasticity
measurements; LB, Luria-Bertani; MIC, minimum inhibitory
concentration; MIC50, concentration of the antibiotic that
inhibited bacterial growth by 50%; MRSA, methicillin-resis-
tant Staphylococcus aureus; PBS, phosphate-buffered saline;
PCS, photon correlation spectroscopy; PDI, polydispersity
index; PGLs, propylene glycol liposomes; qPCR, quantitative
polymerase chain reaction; rp, pore size of the membrane in
elasticity measurements; rv, average diameter of the liposomes
after passage through a deﬁned membrane in elasticity mea-
surements; SLPC-80, monoacyl phosphatidylcholine from
soybean; SPC-3, hydrogenated soybean phosphatidylcholine;
VFS, vaginal ﬂuid simulant.
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